Cargando…

Risk of regorafenib-induced cardiovascular events in patients with solid tumors: A systematic review and meta-analysis

BACKGROUND: The present comparative meta-analysis was conducted to evaluate the cardiovascular events of regorafenib in patients with solid tumors. METHODS: Eligible studies from MEDLINE, Google Scholar, Cochrane Library, Clinical key, EBSCO publishing and Ovid, which had reported cardiovascular adv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jianxin, Wang, Junhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer Health 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203579/ https://www.ncbi.nlm.nih.gov/pubmed/30313066 http://dx.doi.org/10.1097/MD.0000000000012705

Ejemplares similares

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials
por: Yin, Xiaonan, et al.
Publicado: (2018)

Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials
por: Chen, Jianxin, et al.
Publicado: (2019)

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2021)

Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis
por: Facciorusso, Antonio, et al.
Publicado: (2019)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis
por: Rizzo, Alessandro, et al.
Publicado: (2020)

Prevention and management of adverse events related to regorafenib
por: De Wit, Mieke, et al.
Publicado: (2013)

Correction: Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2019)

The Role of Regorafenib in the Management of Advanced Gastrointestinal Stromal Tumors: A Systematic Review
por: Khachatryan, Vahe, et al.
Publicado: (2022)

Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Clarithromycin use and the risk of mortality and cardiovascular events: A systematic review and meta-analysis
por: You, Ching-Hui, et al.
Publicado: (2019)

Major adverse cardiac events and cardiovascular toxicity with PARP inhibitors-based therapy for solid tumors: a systematic review and safety meta-analysis
por: Palazzo, A., et al.
Publicado: (2023)

Erratum to: Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics
por: Sunakawa, Yu, et al.
Publicado: (2013)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Febuxostat and Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Cuenca, John A., et al.
Publicado: (2019)

Targeting gastrointestinal stromal tumors: the role of regorafenib
por: Schroeder, Brett, et al.
Publicado: (2016)

Ideal Cardiovascular Health and Risk of Cardiovascular Events or Mortality: A Systematic Review and Meta-Analysis of Prospective Studies
por: Radovanovic, Milan, et al.
Publicado: (2023)

Incidence and risk of hypertension with lenvatinib in treatment of solid tumors: An updated systematic review and meta‐analysis
por: Wu, Hongxiao, et al.
Publicado: (2022)

Comparison of efficacy and safety of S-1 and capecitabine in patients with metastatic colorectal carcinoma: A systematic review and meta-analysis
por: Chen, Jianxin, et al.
Publicado: (2019)

Ramadan fasting is not usually associated with the risk of cardiovascular events: A systematic review and meta-analysis
por: Turin, Tanvir C., et al.
Publicado: (2016)

The association of serum C-peptide with the risk of cardiovascular events: a meta-analysis and systematic review
por: Jahromi, Mitra Kazemi, et al.
Publicado: (2023)

Cardiovascular events and risk in patients with systemic lupus erythematosus: Systematic literature review and meta-analysis
por: Bello, Natalia, et al.
Publicado: (2022)

Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma
por: Chen, Jianxin, et al.
Publicado: (2020)

The Association of Overt and Subclinical Hyperthyroidism with the Risk of Cardiovascular Events and Cardiovascular Mortality: Meta-Analysis and Systematic Review of Cohort Studies
por: Sohn, Seo Young, et al.
Publicado: (2020)

Risk Factors of the Recurrences of Pancreatic Solid Pseudopapillary Tumors: A Systematic Review and Meta-analysis
por: Gao, Hao, et al.
Publicado: (2018)

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis
por: He, Yang, et al.
Publicado: (2019)

The Biological Disease-Modifying Antirheumatic Drugs and the Risk of Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Hu, Suiyuan, et al.
Publicado: (2021)

Serum copper levels and risk of major adverse cardiovascular events: a systematic review and meta-analysis
por: Muñoz-Bravo, Carlos, et al.
Publicado: (2023)

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

Regorafenib plus Vincristine and Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors: An Innovative Therapy for Children with Cancer Study
por: Casanova, Michela, et al.
Publicado: (2023)

A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
por: Xue, Wu-Song, et al.
Publicado: (2018)

The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis
por: Murad, M Hassan, et al.
Publicado: (2012)

Association of Vitamin D Supplementation with Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Pei, Yi-Yan, et al.
Publicado: (2022)

Efficacy and safety of regorafenib as beyond second-line therapy in patients with metastatic colorectal cancer: an adjusted indirect meta-analysis and systematic review
por: Wu, Yinying, et al.
Publicado: (2020)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Bisphosphonates and Risk of Cardiovascular Events: A Meta-Analysis
por: Kim, Dae Hyun, et al.
Publicado: (2015)

Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
por: Prochaska, Judith J, et al.
Publicado: (2012)

Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis
por: Yang, Jie, et al.
Publicado: (2022)

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule
por: Grimaudo, Maria Susanna, et al.
Publicado: (2023)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_f49rqvnqbv6aq759nsp6c2nudt